Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson’s Disease: Online-Based Delphi Survey
Background. Safinamide is a selective, reversible monoamine oxidase-B inhibitor with a sodium channel inhibitory effect. Published clinical evidence supports safinamide as an effective therapy for Parkinson’s disease (PD) with wearing-off. However, to date, no consensus recommendations have been ava...
Saved in:
Main Authors: | Atsushi Takeda, Yoshio Tsuboi, Masahiro Nomoto, Hideki Mochizuki, Nobutaka Hattori |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2022/3203212 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Focus on Depression in Parkinson’s Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics
by: Luis Agüera-Ortiz, et al.
Published: (2021-01-01) -
Stability-indicating spectrophotometric quantification of safinamide in the presence of its possible degradation product
by: Ebraam B. Kamel, et al.
Published: (2025-01-01) -
Expert Consensus on the Management of Acute Otitis Media in India: A Delphi Study
by: Tanu Singhal, et al.
Published: (2024-05-01) -
Pain science education concepts for pelvic pain: an e-Delphi of expert clinicians
by: Amelia K. Mardon, et al.
Published: (2025-02-01) -
Expert consensus on the benefits of neuraminidase in conventional influenza vaccines: a Delphi study
by: John Youhanna, et al.
Published: (2025-01-01)